| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 07/06/2004 | US6759422 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 07/06/2004 | US6759415 Affinity with subtypes of somatostatin receptors |
| 07/06/2004 | US6759412 For producing drugs used for therapy of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis |
| 07/06/2004 | US6759406 Quaternary ammonium compounds |
| 07/06/2004 | US6759208 Prevention, therapy disease; forming tritiated water; calibration |
| 07/06/2004 | US6759194 Nucleotide sequences encoding peroxisome-associated polypeptides, and their uses in the diagnosis and/or treatment of lung injuries and diseases, and of oxidative stress-related disorders |
| 07/01/2004 | WO2004054987A1 Cathepsin cysteine protease inhibitors and their use |
| 07/01/2004 | WO2004054567A1 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause |
| 07/01/2004 | WO2004054514A2 C-6 modified indazolylpyrrolotriazines |
| 07/01/2004 | WO2004046199A3 Novel method of obtaining chondroitin sulphuric acid and uses thereof |
| 07/01/2004 | WO2004043912A3 Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| 07/01/2004 | WO2004041859A3 Peptide fragments of the harp factor inhibiting angiogenesis |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2003099844A3 Protease inhibitors |
| 07/01/2004 | WO2003093297A3 Protein kinase modulators and methods of use |
| 07/01/2004 | WO2003092605A3 Protease inhibitors |
| 07/01/2004 | WO2003086325A3 Cyanamides useful as reversible inhibitors of cysteine proteases |
| 07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/01/2004 | WO2002015846A3 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 07/01/2004 | WO1998008480A3 Method of using tetracycline compounds for inhibition of nitric oxide production |
| 07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
| 07/01/2004 | US20040127712 Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors |
| 07/01/2004 | US20040127707 Novel phthalazinones |
| 07/01/2004 | US20040127699 Cosmetics, drugs |
| 07/01/2004 | US20040127576 Estrogen receptor modulators |
| 07/01/2004 | US20040127547 Prodigiosin composition for the treatment of rheumatic arthritis |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127536 Indazole Derivatives |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127513 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
| 07/01/2004 | US20040127498 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127466 treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040126825 Using a compounds ability to decrease integrin activation as a diagnostic tool for the identification of antagonistic modulators of neovascularizaton; antitumor/antiproliferative agents |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126758 homologous to the known fibrinogen derived haptotactic peptides; shown to elicit activity from fibroblasts, endothelial and smooth muscle cells; for wound healing and enhancing osteogenesis/angiogenesis in vivo with/without medical implant |
| 07/01/2004 | US20040126447 Extract of Dioscorea sp. and the medical uses thereof |
| 07/01/2004 | US20040126364 Antiinflammatory agents; genetic engineered interleukins; oral diseases |
| 06/30/2004 | EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 06/30/2004 | EP1433780A1 19-nor-vitamin D3 compounds with calcemic activity |
| 06/30/2004 | EP1433487A1 Method of bone regeneration |
| 06/30/2004 | EP1433388A1 Algae-based food supplement |
| 06/30/2004 | EP1432991A1 Identification and isolation of somatic stem cells and uses thereof |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432735A2 Antagonistic anti-htnfsf13b human antibodies |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432708A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432445A2 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex |
| 06/30/2004 | EP1432438A2 Use of rank antagonists to treat cancer |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432427A1 Composition of hypochlorous acid and its applications |
| 06/30/2004 | EP1432421A1 Quinoline derivatives as neuropeptide y antagonists |
| 06/30/2004 | EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/30/2004 | EP1432413A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432312A1 Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues |
| 06/30/2004 | EP1267916B1 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance |
| 06/30/2004 | EP1149072B1 Sulfonamide hydroxamates |
| 06/30/2004 | EP1082299B1 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments |
| 06/30/2004 | EP0971908B1 Il-8 receptor antagonists |
| 06/30/2004 | EP0855884B1 Bone grafting matrix |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509328A Use of opg ligand to modulate immune response |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509283A Novel pyridyl cyanoguandine compounds |
| 06/30/2004 | CN1509281A Benzimidazol derivatives modulate che mokine receptors |
| 06/30/2004 | CN1509276A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509274A Metallo proteinase inhibitors |
| 06/30/2004 | CN1509273A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509272A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509271A 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for treatment of pain anxiety or gastrointestinal disorders |
| 06/30/2004 | CN1509165A Liquid pharmaceutical composition |
| 06/30/2004 | CN1507901A Joint-promoting, bone-through and pain-relieving liquid |
| 06/30/2004 | CN1507893A Composition for anti osteo porosis |
| 06/30/2004 | CN1507892A Osteoproliferation medicine for external application |
| 06/30/2004 | CN1507880A Medicinal composition for treating rheumatoid |
| 06/30/2004 | CN1155600C 2,3-diaryl-pyrazolo[1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2(cox-2) inhibitors |
| 06/30/2004 | CN1155589C Compounds and methods for modulation of estroglen receptors |
| 06/30/2004 | CN1155571C Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith |
| 06/30/2004 | CN1155387C Phosphonate medicine for treating osteoporosis and bone cancer transfer |
| 06/29/2004 | US6756491 Receptor polypeptide for use in the treatment of urogenital disorders and cushing's syndrome |
| 06/29/2004 | US6756481 IL-23 receptor binding compositions |
| 06/29/2004 | US6756480 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/29/2004 | US6756406 Antiarthritic agents; rheumatic diseases; osteoarthritis; inhibition of the inducible nitric oxide synthase - induced after activation of vascular smooth muscle, macrophages, endothelial cells by enotoxin and cytokines |
| 06/29/2004 | US6756401 Drug mixtures comprising estrogen agonists or antagonists and anticholesterol statins, administered to promote bone formation, prevent bone disorders and/or as anticholesterol agents |
| 06/29/2004 | US6756391 Antiviral compounds |
| 06/29/2004 | US6756381 A purified antitumor agent is crystallized from acetone or dichloromethane |